Actively Recruiting
Artificial Intelligence for Diagnosing Diabetic Retinopathy in Primary Care
Led by Hospital de Clinicas de Porto Alegre · Updated on 2025-11-19
922
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
Sponsors
H
Hospital de Clinicas de Porto Alegre
Lead Sponsor
F
Fundação de Amparo à Pesquisa do Estado de São Paulo
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a clinical trial to evaluate the effects of universal screening for diabetic retinopathy (DR) and diabetic macular edema (DME) using artificial intelligence (AI) in the interpretation of fundus photographs obtained by trained nursing assistant using a portable fundus camera in a primary care setting, compared with images obtained by the same method, but interpreted by ophthalmologists.
CONDITIONS
Official Title
Artificial Intelligence for Diagnosing Diabetic Retinopathy in Primary Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (> 18 years old) diagnosed with diabetes mellitus who agree to participate in the study.
You will not qualify if you...
- Any contraindication for pharmacological mydriasis, such as closed-angle glaucoma or pregnancy.
- Life expectancy less than 6 months.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
Actively Recruiting
Research Team
B
Beatriz D Schaan, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here